SomnoMed Limited (SOMNF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
SomnoMed Limited (SOMNF) trades at $0.45 with AI Score 52/100 (Grade B). SomnoMed Limited focuses on developing and selling oral devices for sleep-related disorders. Market cap: $98.59M, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for SOMNF: SOMNF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SOMNF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
SOMNF: 4/6 perspectives are bullish. Dominant signal: Izzy Englander bullish.
How is this calculated? →SomnoMed Limited (SOMNF) Healthcare & Pipeline Overview
SomnoMed Limited specializes in oral appliance therapy for sleep-related disorders, offering SomnoDent for obstructive sleep apnea and SomnoBrux for teeth grinding. With a presence in Europe, North America, and Asia Pacific, the company addresses a significant market need, though profitability remains a challenge with a negative profit margin.
What Is the Investment Thesis for SOMNF?
SomnoMed Limited presents a focused play on the growing market for sleep disorder treatments, particularly obstructive sleep apnea. The company's SomnoDent device offers a patient-friendly alternative to CPAP machines, potentially driving adoption and revenue growth. Key value drivers include expanding market penetration in existing regions and entering new geographic markets. The company's gross margin of 57.4% indicates strong pricing power. However, the negative P/E ratio of -54.24 and a negative profit margin of -2.2% highlight profitability challenges. Upcoming catalysts include potential regulatory approvals in new markets and the introduction of next-generation oral appliance technology. Investors should monitor the company's ability to improve its financial performance and achieve sustainable profitability.
Based on FMP financials and quantitative analysis
SOMNF Key Highlights
- Market capitalization of $98.59M indicates a small-cap company with potential for growth.
- Gross margin of 57.4% demonstrates strong pricing power in the oral appliance market.
- Beta of 0.94 suggests the stock is slightly less volatile than the overall market.
- Negative P/E ratio of -54.24 reflects current unprofitability, requiring careful monitoring.
- Presence in Europe, North America, and Asia Pacific provides geographic diversification.
Who Are SOMNF's Competitors?
SOMNF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AURX Nuo Therapeutics, Inc. | $0.96 | -4.95% | $46.47M | 61 |
| CORBF Global Cord Blood Corporation | $0.95 | +0.00% | $127.35M | 53 |
| GRUSF Grown Rogue International Inc. | $0.47 | +2.35% | $117.67M | 43 |
| LDXHF Lumos Diagnostics Holdings Limited | $0.08 | +0.00% | $61.07M | 40 |
| ORXOF Orexo AB (publ) | $2.90 | +38.10% | $101.87M | 50 |
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SOMNF's Key Strengths?
- Specialized in oral appliance therapy for sleep disorders.
- Proprietary SomnoDent technology.
- Presence in multiple geographic regions.
- Strong gross margin.
What Are SOMNF's Weaknesses?
- Negative profit margin.
- High P/E ratio due to unprofitability.
- Reliance on dental professionals for distribution.
- Limited product diversification.
What Could Drive SOMNF Stock Higher?
- Potential regulatory approvals for SomnoDent in new geographic markets.
- Launch of next-generation oral appliance technology with improved comfort and efficacy.
- Increasing awareness of obstructive sleep apnea and the benefits of oral appliance therapy.
- Expansion of partnerships with dental professionals and sleep specialists.
- Efforts to secure broader reimbursement coverage for SomnoDent from insurance companies.
What Are the Key Risks for SOMNF?
- Negative return on equity (-5.3%) — the business is not currently generating profit on shareholder capital.
- Competition from established players in the sleep disorder treatment market (e.g., CPAP manufacturers).
- Regulatory changes and reimbursement policies impacting market access and pricing.
- Unprofitability and negative cash flow.
- Reliance on dental professionals for distribution and patient referrals.
- Product liability claims and recalls.
What Are the Growth Opportunities for SOMNF?
- Expanding market penetration in existing regions: SomnoMed can increase sales by targeting a larger share of the obstructive sleep apnea market in Europe, North America, and the Asia Pacific region. This involves strengthening partnerships with dental professionals and sleep specialists, increasing marketing efforts, and improving patient awareness. The global sleep apnea devices market is projected to reach $11.2 billion by 2028, providing a substantial opportunity for growth.
- Entering new geographic markets: SomnoMed can expand its geographic footprint by entering new markets with a high prevalence of sleep disorders. This requires obtaining regulatory approvals, establishing distribution networks, and adapting its products to local market needs. Emerging markets in Asia and Latin America offer significant growth potential.
- Developing and launching new products: SomnoMed can drive growth by investing in research and development to create innovative oral appliance therapies. This includes developing next-generation devices with improved comfort, efficacy, and patient compliance. The company can also explore new applications for its technology, such as treating snoring or temporomandibular joint (TMJ) disorders.
- Increasing adoption of SomnoBrux: SomnoMed can increase sales of SomnoBrux by targeting the market for teeth grinding and bruxism. This involves educating dental professionals and patients about the benefits of SomnoBrux and expanding its distribution channels. The market for dental guards and oral splints is growing, driven by increased awareness of the damaging effects of teeth grinding.
- Improving reimbursement coverage: SomnoMed can improve its financial performance by securing broader reimbursement coverage for its products from insurance companies and government healthcare programs. This requires demonstrating the clinical and economic value of its oral appliance therapies and working with payers to establish favorable reimbursement policies. Increased reimbursement coverage would make SomnoDent and SomnoBrux more accessible to patients.
What Opportunities Does SOMNF Have?
- Expanding market penetration in existing regions.
- Entering new geographic markets.
- Developing new oral appliance therapies.
- Increasing reimbursement coverage.
What Threats Does SOMNF Face?
- Competition from CPAP machines and other treatments.
- Regulatory changes and reimbursement policies.
- Economic downturns affecting patient spending.
- Product liability claims.
What Are SOMNF's Competitive Advantages?
- Proprietary SomnoDent technology with custom-fit design.
- Established relationships with dental professionals and sleep specialists.
- Brand recognition in the oral appliance therapy market.
- Geographic diversification across Europe, North America, and Asia Pacific.
What Does SOMNF Do?
SomnoMed Limited, established in 1987 and headquartered in Crows Nest, Australia, is a medical device company dedicated to treating sleep-related disorders. The company's core product is SomnoDent, an oral appliance designed to alleviate obstructive sleep apnea (OSA). This device is custom-fitted by dentists and worn during sleep to keep the airway open. In addition to SomnoDent, SomnoMed offers SomnoBrux, a dental guard used to mitigate teeth grinding damage, and SomMorning Repositioner, which aids in returning the mandible to its pre-treatment position. SomTabs are also available for cleaning oral devices. SomnoMed distributes its products across Europe, North America, and the Asia Pacific region, partnering with dental professionals and sleep specialists to reach patients. The company's focus on oral appliance therapy provides an alternative to traditional treatments like CPAP machines, appealing to patients seeking a more comfortable and convenient solution. Despite its innovative products and global presence, SomnoMed faces challenges in achieving profitability, as reflected in its negative profit margin of -2.2%. The company continues to invest in research and development to enhance its product offerings and expand its market reach.
What Products and Services Does SOMNF Offer?
- Develop and manufacture oral appliances for sleep-related disorders.
- Offer SomnoDent, an oral appliance for obstructive sleep apnea.
- Provide SomnoBrux, a dental guard for teeth grinding.
- Distribute products in Europe, North America, and Asia Pacific.
- Partner with dental professionals and sleep specialists.
- Offer SomMorning Repositioner to return mandible to pre-treatment position.
- Provide SomTabs for cleaning oral devices.
How Does SOMNF Make Money?
- Manufacture and sell SomnoDent and SomnoBrux devices.
- Generate revenue through direct sales and distribution partnerships.
- Focus on oral appliance therapy for sleep-related disorders.
- Target dental professionals and sleep specialists as key customers.
What Industry Does SOMNF Operate In?
The medical device industry is characterized by innovation, regulatory scrutiny, and evolving patient needs. The market for sleep disorder treatments is growing, driven by increased awareness of conditions like obstructive sleep apnea and a growing aging population. SomnoMed competes with companies offering CPAP machines, surgical interventions, and other oral appliances. The industry is subject to regulatory approvals and reimbursement policies, which can impact market access and adoption. SomnoMed's focus on oral appliance therapy positions it within a niche segment of the broader sleep disorder market.
Who Are SOMNF's Key Customers?
- Patients with obstructive sleep apnea.
- Patients with teeth grinding (bruxism).
- Dental professionals (dentists, orthodontists).
- Sleep specialists and sleep clinics.
How SomnoMed Limited Is Valued
SomnoMed Limited carries a market capitalization of $98.59M, placing it in the micro-cap category. Relative to its peer group, SOMNF's quantitative score of 52/100 is roughly in line with the peer average of 49/100.
Company Profile
SomnoMed Limited operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Crows Nest, AU. The company is led by CEO Amrita Blickstead. SOMNF has traded publicly since 2010.
ROE -5%Key Financial Metrics
Return on equity for SomnoMed Limited stands at -5.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -3.2%, showing how much profit it generates from its asset base. Its free cash flow yield is 3.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.76 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -2.3%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 6/9Financial Health
SomnoMed Limited's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 4.45 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project SomnoMed Limited revenue of about $121.4M for fiscal 2026, with EPS near $0.01. The estimate reflects 3 contributing analysts.
SOMNF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Insider buying has increased recently, indicating confidence in the company's future performance.
- Positive community sentiment has been observed, with discussions highlighting the effectiveness of SomnoMed's sleep apnea solutions.
- Recent partnerships have expanded market reach, suggesting potential for increased sales and brand recognition.
- Innovations in product development are being well-received, enhancing the company's competitive edge in the healthcare sector.
Bear Case
- Concerns about rising competition in the sleep apnea market could pressure SomnoMed's market share.
- Community discussions have noted potential regulatory hurdles that may delay product launches.
- Some analysts express skepticism about the sustainability of recent growth, fearing it may not be backed by solid fundamentals.
- Market perception has been cautious, with some investors worried about the overall economic climate impacting healthcare spending.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SOMNF Latest News
No recent news available for SOMNF.
SOMNF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SOMNF.
Price Targets
Wall Street price target analysis for SOMNF.
SOMNF MoonshotScore
What does this score mean?
The MoonshotScore rates SOMNF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Amrita Blickstead
CEO
Amrita Blickstead is the Chief Executive Officer of SomnoMed Limited. Her background includes extensive experience in the healthcare industry, with a focus on medical devices and diagnostics. She has held leadership roles in various multinational companies, overseeing strategic planning, product development, and commercial operations. Blickstead's expertise lies in driving growth and innovation in the healthcare sector, with a track record of successfully launching new products and expanding market share.
Track Record: Since becoming CEO, Amrita Blickstead has focused on expanding SomnoMed's global reach and improving its financial performance. Key initiatives include strengthening partnerships with dental professionals, investing in research and development, and streamlining operations. Under her leadership, the company has launched new products and expanded its presence in key markets. However, profitability remains a challenge.
SOMNF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that SomnoMed Limited may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Limited regulatory oversight.
- Verify the company's financial statements and disclosures.
- Assess the company's management team and track record.
- Research the company's products and market position.
- Evaluate the company's legal and regulatory compliance.
- Monitor trading volume and price volatility.
- Consult with a financial advisor.
- Understand the risks associated with OTC investing.
- Established history since 1987.
- Presence in multiple geographic regions.
- Focus on a specific niche market (sleep disorders).
- Partnerships with dental professionals and sleep specialists.
What Investors Ask About SomnoMed Limited (SOMNF) — Healthcare
What does SomnoMed Limited do?
SomnoMed Limited specializes in the development, manufacturing, and distribution of oral appliance therapies for the treatment of sleep-related disorders, primarily obstructive sleep apnea (OSA) and bruxism (teeth grinding). The company's flagship product, SomnoDent, is a custom-fitted oral appliance prescribed by dentists and sleep specialists to keep the airway open during sleep, providing an alternative to CPAP machines. SomnoMed also offers SomnoBrux for teeth grinding. The company operates in Europe, North America, and the Asia Pacific region, targeting dental professionals and sleep clinics as key customers.
What do analysts say about SOMNF stock?
As of March 17, 2026, there is no readily available analyst consensus on SOMNF stock due to its OTC listing and limited coverage. Key valuation metrics to consider include its market capitalization of $98.59M, gross margin of 57.4%, and negative P/E ratio of -54.24. Growth considerations include the increasing prevalence of sleep disorders, the potential for market expansion, and the company's ability to achieve profitability. Investors should conduct their own due diligence and consult with a financial advisor before making any investment decisions.
What are the main risks for SOMNF?
SomnoMed Limited faces several risks, including competition from established players in the sleep disorder treatment market, such as CPAP manufacturers. Regulatory changes and reimbursement policies could impact market access and pricing. The company's unprofitability and negative cash flow pose financial challenges. Reliance on dental professionals for distribution and patient referrals creates dependence on a specific channel. Product liability claims and recalls are potential risks associated with medical devices. Additionally, as an OTC-listed company, SOMNF is subject to risks related to limited liquidity and transparency.
What are the key factors to evaluate for SOMNF?
SomnoMed Limited (SOMNF) holds an AI score of 52/100 (moderate). Not financial advice.
How frequently does SOMNF data refresh on this page?
SOMNF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven SOMNF's recent stock price performance?
SomnoMed Limited (SOMNF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized in oral appliance therapy for sleep disorders. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SOMNF overvalued or undervalued right now?
Valuing SomnoMed Limited (SOMNF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying SOMNF?
Before investing in SomnoMed Limited (SOMNF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on available information and may be subject to change.
- Analyst consensus is not available due to limited coverage.
- OTC market carries inherent risks.